Patient P-02206
Synthetic patientMETA-24 · Day 122 · 25–34 · F · baseline S05Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Favorable
Nutritional resilience
Improving
Discontinuation risk
13%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S05
- Day 31 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 31.
Primary contributors, last 14 days
- GI instability-10
- Nutritional resilience+8
- Treatment adherence+5
- Toxicity+5
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable61 min
stable · +2.3 vs previous 14 d
Sleep duration
Wearable7.2 h
stable · -0.2 vs previous 14 d
Energy level
Daily log5.6/10
stable · +0.0 vs previous 14 d
Steps
Wearable5,913
stable · +101 vs previous 14 d
GI burden
Companion16.1/100
stable · +0.4 vs previous 14 d
Adherence
Companion85.2 %
stable · -0.3 vs previous 14 d
Sleep quality
Wearable64.1/100
worsening · -2.9 vs previous 14 d
Glucose, CGM daily mean
CGM131 mg/dL
stable · +2.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 68 from the failing basin, 44 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -6.7 next day on high-intake days · n 27
Would not help
- BR-03 Behavioural Recommendationonly 30% improved among 10 similar
- Keep caffeine lowGI +5.5 next day on high-intake days · n 20
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-6.7supporter · 95%
- Caffeine+5.5detractor · 95%
- Insoluble fibre+1.8no signal · 31%
- Simple carbohydrates-1.7no signal · 33%
- Alcohol-1.3no signal · 20%
- Dietary fat load-0.7no signal · 15%
- Ultra-processed food+0.5no signal · 15%
- Histamine load-0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 4.2 · butyrate capacity 67/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 66 ms
- Sleep
- 7.3 h
- Steps
- 7,427
- Resting HR
- 58 bpm
Daily log: GI score 16, nutritional resilience 65, adherence 85.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02438 | 48% | S01 | — | — | 32 |
| P-02269 | 39% | S01 | — | — | 27 |
| P-02522 | 39% | S01 | BR-03 | no change | 40 |
| P-02662 | 33% | S01 | — | — | 20 |
| P-02041 | 32% | S01 | — | — | 27 |
| P-02087 | 32% | S01 | BR-03 | no change | 40 |
| P-02375 | 32% | S01 | — | — | 44 |
| P-02218 | 28% | S01 | DT-01 | improved | 61 |
| P-02638 | 27% | S01 | BR-03 | improved | 41 |
| P-02437 | 26% | S01 | — | — | 64 |
| P-02568 | 26% | S01 | — | — | 51 |
| P-02681 | 26% | S01 | — | — | 51 |